ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Elan Takes Stake In Theravance Programs

by Rick Mullin
May 20, 2013 | APPEARED IN VOLUME 91, ISSUE 20

Elan and Theravance have entered a royalty agreement under which the Irish drug firm will pay Theravance $1 billion for an interest in possible future royalty payments related to four respiratory programs that Theravance is working on with GlaxoSmithKline. Under the agreement, Elan will make a one-time payment for a 21% stake in the royalties that would accrue if Theravance advances any of the programs to commercialization. Elan, which has divested all of its physical assets over the past three years, has refused a $7.3 billion acquisition bid from Royalty Pharma.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment